Acacia Pharma Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.acaciapharma.com
Clinical Trials
31
Active:14
Completed:16
Trial Phases
3 Phases
Phase 1:12
Phase 2:7
Phase 3:6
Drug Approvals
2
FDA:2
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 1
12 (48.0%)Phase 2
7 (28.0%)Phase 3
6 (24.0%)A study of intravenous amisulpride as prevention of post-operative nausea and vomiting in children
Phase 3
Completed
- Conditions
- post-operative nausea and vomiting in pediatric patients
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Acacia Pharma Limited
- Target Recruit Count
- 200
- Registration Number
- 2024-518778-15-00
- Locations
- 🇩🇪
Universitaetsklinikum Bonn AöR, Bonn, Germany
🇩🇪Universitaetsklinikum Wuerzburg AöR, Wuerzburg, Germany
🇩🇪HELIOS Klinikum Aue GmbH, Aue, Germany
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
Withdrawn
- Conditions
- Nausea and Vomiting, Postoperative
- Interventions
- Drug: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Acacia Pharma Ltd
- Registration Number
- NCT04954365
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT04851717
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of California Davis Children's Hospital, Sacramento, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
Phase 1
Completed
- Conditions
- Renal Disease, End Stage
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT04849650
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
Study of APD421 With and Without Ondansetron
Phase 1
Completed
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT03583489
- Locations
- 🇬🇧
Early Phase Clinical Unit, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found